Comparative Pharmacology
Head-to-head clinical analysis: DEXACORT versus PENECORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXACORT versus PENECORT.
DEXACORT vs PENECORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexamethasone is a glucocorticoid receptor agonist that modulates gene expression to produce anti-inflammatory and immunosuppressive effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production.
PENECORT is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression and suppressing inflammation, immune responses, and adrenal function.
Oral: 0.75-9 mg/day in divided doses; IV: 0.5-9 mg/day every 6-12 hours; IM: 4-20 mg every 2 weeks.
2.5-5 mg orally once daily; maximum 10 mg/day. Intramuscular: 20-40 mg every 2-4 weeks.
None Documented
None Documented
Plasma terminal elimination half-life is 2.8-3.5 hours in adults, but the biological half-life (duration of HPA axis suppression) is 24-36 hours due to prolonged receptor occupancy
Terminal elimination half-life: 3-4 hours in adults; prolonged in hepatic impairment (up to 8 hours).
Renal (approximately 80% as inactive metabolites, <5% unchanged), biliary/fecal (minor, approximately 15-20%)
Renal: 60-70% as metabolites, 5-10% unchanged; Biliary/fecal: 20-30% as metabolites.
Category C
Category C
Corticosteroid
Corticosteroid